Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations

Melina E Marmarelis1, Corey J Langer1

  • 1Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

Clinical Lung Cancer
|June 8, 2020
PubMed

Insights

Targeted therapies offer improved outcomes for non-small-cell lung cancer patients with rare oncogenic drivers. This review covers clinical responses to approved and developing targeted agents and discusses molecular testing methods.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) presents a significant global health burden with historically poor prognoses.
  • Advances in understanding oncogenic drivers have led to targeted therapies with improved outcomes for specific patient subsets.
  • Rare oncogenic drivers in NSCLC represent an area of growing therapeutic interest.

Purpose of the Study:

  • To review the clinical efficacy of targeted agents against rare oncogenic drivers in NSCLC.
  • To discuss targeted therapies currently approved and in late-stage clinical development for NSCLC.
  • To outline molecular testing methodologies for identifying oncogenic drivers in NSCLC.

Main Methods:

  • Literature review of clinical trials and studies on targeted therapies for NSCLC.
  • Analysis of response rates and outcomes in patients with rare oncogenic drivers.
  • Overview of diagnostic techniques for molecular profiling in NSCLC.

Main Results:

  • Targeted agents demonstrate clinical activity in NSCLC tumors with specific rare oncogenic drivers.
  • Several approved and investigational therapies show promise for these select populations.
  • Molecular testing is crucial for identifying patients eligible for targeted treatments.

Conclusions:

  • Targeted therapy is revolutionizing NSCLC treatment by addressing specific molecular alterations.
  • Identifying rare oncogenic drivers through molecular testing is essential for personalized treatment strategies.
  • Continued research into novel targeted agents and testing methods is vital for improving NSCLC patient outcomes.
Keywords:
BRAFMETNTRKRETROS1

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

251
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K